Non-small Cell Lung Cancer

CLINICAL_TRIALS research · 2024-11-26

Clinical Trial Update: Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients [Phase 2]

A Phase 2 clinical trial is evaluating tislelizumab as consolidation immunotherapy after radiotherapy or sequential chemoradiation in patien…

CLINICAL_TRIALS research · 2024-11-26

Clinical Trial Update: Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer [Phase 2]

BEBT-109 is being studied in a Phase 2 clinical trial for non-small cell lung cancer with EGFR Exon 20 insertion mutations; the study is cur…

CLINICAL_TRIALS trial_result · 2024-11-25

Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer [Phase 3]

Phase 3 trial comparing tislelizumab to chemotherapy in advanced non-squamous non-small cell lung cancer has completed with results posted.

CLINICAL_TRIALS research · 2024-11-25

Clinical Trial Update: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations [Phase 3]

Phase 3 trial evaluating Aumolertinib, with or without chemotherapy, as first-line treatment for locally advanced or metastatic non-small ce…

CLINICAL_TRIALS trial_result · 2024-11-25

Clinical Trial Update: Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC [Phase 1]

A Phase 1 trial evaluating atovaquone in combination with radical chemoradiotherapy for locally advanced non-small cell lung cancer has comp…

CLINICAL_TRIALS withdrawal · 2024-11-25

Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…

CLINICAL_TRIALS research · 2024-11-25

Clinical Trial Update: Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases [Phase 2]

Phase 2 clinical trial evaluating cadonilimab in combination with stereotactic radiotherapy as a second-line treatment for brain metastases …

CLINICAL_TRIALS research · 2024-11-25

Clinical Trial Update: Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

A clinical trial evaluating a radiolabeled Nectin-4 targeted low-molecular-weight probe for PET/CT imaging in patients with lung lesions, cu…

CLINICAL_TRIALS trial_result · 2024-11-25

Clinical Trial Update: A Study of NDI 1150-101 in Patients With Solid Tumors [Phase 1, Phase 2]

Nimbus Saturn, Inc. is conducting a Phase 1/2 trial of NDI 1150-101 in patients with solid tumors, including renal cell carcinoma, gastric c…

CLINICAL_TRIALS trial_result · 2024-11-22

Clinical Trial Update: Supportive Care Mobile Application for Patients With NSCLC [NA]

The document provides an update on a completed clinical trial evaluating a supportive care mobile application for patients with non-small ce…

CLINICAL_TRIALS research · 2024-11-22

Clinical Trial Update: Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC [Phase 2]

ClinicalTrials.gov report describes a Phase 2 neoadjuvant trial in resectable non-small cell lung cancer evaluating chemotherapy and immunot…

CLINICAL_TRIALS research · 2024-11-22

Clinical Trial Update: Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis [Phase 2]

Phase II clinical study evaluating the combination of Adebrelimab and Apatinib in unresectable locally advanced non-small cell lung cancer, …

CLINICAL_TRIALS trial_result · 2024-11-21

Clinical Trial Update: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer [Phase 2]

Phase 2 study comparing preferences for subcutaneous versus intravenous atezolizumab in non-small cell lung cancer has completed, with resul…

CLINICAL_TRIALS research · 2024-11-21

Clinical Trial Update: Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Clinical trial update describing predictive multimodal signatures linked to treatment response and prognosis in patients with stage IV non-s…

CLINICAL_TRIALS research · 2024-11-21

Clinical Trial Update: TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases [Phase 2]

TYK Medicines is conducting a Phase 2 trial of TY-9591 for patients with EGFR-mutant non-small cell lung cancer, including those with brain …

CLINICAL_TRIALS research · 2024-11-20

Clinical Trial Update: Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients [Phase 2]

Phase 2 clinical trial evaluating cerebrospinal fluid immune microenvironment mechanisms in ALK-positive non-small cell lung cancer. The stu…

CLINICAL_TRIALS trial_result · 2024-11-20

Clinical Trial Update: A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]

Phase 1 study of ASP8273 in EGFR-mutated non-small cell lung cancer has been terminated.

CLINICAL_TRIALS withdrawal · 2024-11-20

Clinical Trial Update: AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC [Phase 2]

Phase 2 trial evaluating the combination of sotorasib (AMG510) and lenvatinib in KRAS G12C-mutant metastatic non-small cell lung cancer has …

CLINICAL_TRIALS research · 2024-11-20

Clinical Trial Update: Afatinib With CT and RT for EGFR-Mutant NSCLC [Phase 2]

A Phase 2 clinical trial at Massachusetts General Hospital is evaluating afatinib with concurrent chemotherapy and radiotherapy for EGFR-mut…

CLINICAL_TRIALS trial_result · 2024-11-20

Clinical Trial Update: A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations [Phase 2]

Phase 2 trial of ASP8273 in EGFR-mutant, EGFR-TKI–naïve non-small cell lung cancer has been terminated.